Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
367
datasets available to search
ShareScore release 0.9.0
Dataset results
367 results for “Ibrutinib”
Study on the Effect of Ibrutinib on High Risk Smoldering Multiple Myeloma Patients
ClinicalTrials.gov study NCT02943473. IPD Sharing: Not stated. Countries: 1. Publications: 0.
TGR-1202 and Ibrutinib in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
ClinicalTrials.gov study NCT02874404. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Study of Ibrutinib in Combination With Pomalidomide and Dexamethasone in Subjects With Relapsed/Refractory Multiple Myeloma
ClinicalTrials.gov study NCT02548962. IPD Sharing: Not stated. Countries: 6. Publications: 0.
Testing the Addition of a New Anti-cancer Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Obinutuzumab) in Untreated, Older Patients With Chronic Lymphocytic Leukemia
ClinicalTrials.gov study NCT03737981. IPD Sharing: YES. Countries: 1. Publications: 0.
A Phase I/II Study of Ibrutinib in Previously Treated Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer
ClinicalTrials.gov study NCT02321540. IPD Sharing: Not stated. Countries: 1. Publications: 0.
A Study of Epcoritamab and Ibrutinib in People With Central Nervous System Lymphoma (CNSL)
ClinicalTrials.gov study NCT07082868. IPD Sharing: YES. Countries: 1. Publications: 0.
Ibrutinib, Fludarabine, and Pembrolizumab in High-Risk or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
ClinicalTrials.gov study NCT03204188. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Ibrutinib in Patients With Refractory/Relapsed Non-GCB Diffuse Large B-cell Lymphoma Non-candidates to ASCT
ClinicalTrials.gov study NCT02692248. IPD Sharing: NO. Countries: 1. Publications: 0.
Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell Transplant
ClinicalTrials.gov study NCT02869633. IPD Sharing: UNDECIDED. Countries: 1. Publications: 0.
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (VIPOR) for Diffuse Large B-cell Lymphoma Involving the Central Nervous System
ClinicalTrials.gov study NCT05211336. IPD Sharing: YES. Countries: 1. Publications: 0.
Study of Ibrutinib vs Placebo, in Combination With Nab-paclitaxel and Gemcitabine, in the First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma (RESOLVE)
ClinicalTrials.gov study NCT02436668. IPD Sharing: Not stated. Countries: 8. Publications: 0.
Ibrutinib and Rituxan for Chronic GVHD
ClinicalTrials.gov study NCT04235036. IPD Sharing: NO. Countries: 1. Publications: 0.
A Phase 1/2, Open-label, Dose Finding Study to Evaluate CC-122 in Combination With Ibrutinib and Obinutuzumab in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
ClinicalTrials.gov study NCT02406742. IPD Sharing: Not stated. Countries: 5. Publications: 0.
Study of BTK Inhibitor, Ibrutinib in Combination With Carfilzomib in Subjects With Relapsed and Refractory Multiple Myeloma
ClinicalTrials.gov study NCT01962792. IPD Sharing: Not stated. Countries: 2. Publications: 0.
A Study of Ibrutinib With Rituximab in Relapsed or Refractory Mantle Cell Lymphoma
ClinicalTrials.gov study NCT05564052. IPD Sharing: YES. Countries: 13. Publications: 0.
Study of Ibrutinib & Obinutuzumab With/Without CHOP for Richter's Transformation or Richter's Syndrome Patients
ClinicalTrials.gov study NCT03145480. IPD Sharing: NO. Countries: 1. Publications: 0.
Data from: Inhibition of BTK and ITK with ibrutinib is effective in the prevention of chronic graft-versus-host disease in mice
Open the record for dataset details and reuse information.
RNA-Seq for a differential gene expression bewteen KLHL14 wild-type(+/+) and KLHL14 knockout(-/-) TMD8 ABC-DLBCL cell line upon treatment with a BTK inhibitor, ibrutinib
GEO Series GSE141143. Homo sapiens. 8 samples. Type: Expression profiling by high throughput sequencing.
CD52 and OXPHOS - potential targets in ibrutinib treated mantle cell lymphoma
GEO Series GSE214725. Homo sapiens. 12 samples. Type: Expression profiling by high throughput sequencing.
Treatment of MEC1, EHEB and JVM2 leukemia cell lines with fludarabine, ibrutinib and idelalisib
GEO Series GSE135030. Homo sapiens. 36 samples. Type: Expression profiling by high throughput sequencing.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.